Literature DB >> 14569416

Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.

Kohkichi Hata1, Mitsuhiko Osaki, Dipok Kumar Dhar, Kentaro Nakayama, Ritsuto Fujiwaki, Hisao Ito, Naofumi Nagasue, Kohji Miyazaki.   

Abstract

PURPOSE: Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) are major ligands for the endothelium-specific tyrosine kinase receptor Tie-2 and are important regulators of endothelial cell survival. In the presence of vascular endothelial growth factor (VEGF), vessel destabilization by Ang-2 has been hypothesized to induce an angiogenic response, but in the absence of VEGF, Ang-2 leads to vessel regression. In the present study, a human ovarian cancer cell line was used to investigate the possibility that Taxol might affect the expression of Ang-1, Ang-2, and VEGF.
MATERIALS AND METHODS: KF 28, a single-cell clone of a human ovarian epithelial carcinoma cell line, was used. The expression of Ang-1, Ang-2, and VEGF was assessed by quantitative real-time RT-PCR and Western blot analysis or enzyme-linked immunosorbent assay. Conditioned medium was used in the in vitro angiogenesis assay.
RESULTS: The concentration of Taxol that inhibited the growth of cells to the level of 50% of control cell growth was 4.65+/-0.35 nM. Quantitative real-time RT-PCR indicated that Ang-1 gene expression was significantly decreased by exposure to 2 nM Taxol for 168 h ( P<0.05 vs control cells). Western blot analysis confirmed that the Ang-1 protein level was decreased by exposure to 2 nM Taxol for 168 h. Ang-2 gene expression did not significantly differ between control cells and those exposed to Taxol for any of the indicated times. The Ang-1/ Ang-2 gene expression ratio was significantly decreased by exposure to Taxol for 168 h ( P<0.05 vs control cells). VEGF gene expression was significantly decreased by exposure to Taxol for 168 h ( P<0.05). The VEGF concentration in the conditioned medium was also significantly reduced by exposure to Taxol for 168 h ( P<0.05). Conditioned medium collected following Taxol treatment for 168 h significantly inhibited endothelial tubule formation ( P<0.05). Cell growth did not significantly differ between control cells and those exposed to Taxol for any of the indicated times.
CONCLUSIONS: Our results show that exposure of ovarian cancer cells to a low concentration of Taxol may inhibit the initiating event in angiogenesis, namely, vascular regression. This information might be valuable in the development of new therapeutic interventions for epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569416     DOI: 10.1007/s00280-003-0693-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Miller; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

2.  A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; William E Brady; D Scott McMeekin; Peter G Rose; John T Soper; Samuel S Lentz; James S Hoffman; Mark S Shahin
Journal:  Gynecol Oncol       Date:  2011-04-15       Impact factor: 5.482

3.  Metabolic engineering of Nicotiana benthamiana for the increased production of taxadiene.

Authors:  Md Mohidul Hasan; Hyun-Soon Kim; Jae-Heung Jeon; Sung Hong Kim; BoKyung Moon; Jai-Young Song; Sang Hee Shim; Kwang-Hyun Baek
Journal:  Plant Cell Rep       Date:  2014-01-25       Impact factor: 4.570

4.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

5.  The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.

Authors:  Joshua P Kesterson; Paulette Mhawech-Fauceglia; Shashikant Lele
Journal:  Gynecol Oncol       Date:  2008-08-16       Impact factor: 5.482

Review 6.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

Review 7.  Use of Ultrasonication Technology for the Increased Production of Plant Secondary Metabolites.

Authors:  Md Mohidul Hasan; Tufail Bashir; Hanhong Bae
Journal:  Molecules       Date:  2017-06-23       Impact factor: 4.411

Review 8.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

9.  Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  J Cell Mol Med       Date:  2009-10       Impact factor: 5.310

10.  The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.

Authors:  Sofia-Paraskevi Trachana; Eleftherios Pilalis; Nikos G Gavalas; Kimon Tzannis; Olga Papadodima; Michalis Liontos; Alexandros Rodolakis; Georgios Vlachos; Nikolaos Thomakos; Dimitrios Haidopoulos; Maria Lykka; Konstantinos Koutsoukos; Efthimios Kostouros; Evagelos Terpos; Aristotelis Chatziioannou; Meletios-Athanasios Dimopoulos; Aristotelis Bamias
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.